{"id":72848,"date":"2024-08-23T15:24:06","date_gmt":"2024-08-23T15:24:06","guid":{"rendered":"https:\/\/ekamu.net\/?p=72848"},"modified":"2024-08-23T15:24:06","modified_gmt":"2024-08-23T15:24:06","slug":"dunyanin-ilk-mrna-akciger-kanseri-asisi-turkiye-dahil-7-ulkede-denenmeye-basladi","status":"publish","type":"post","link":"https:\/\/ekamu.net\/index.php\/2024\/08\/23\/dunyanin-ilk-mrna-akciger-kanseri-asisi-turkiye-dahil-7-ulkede-denenmeye-basladi\/","title":{"rendered":"D\u00fcnyan\u0131n ilk mRNA akci\u011fer kanseri a\u015f\u0131s\u0131 T\u00fcrkiye dahil 7 \u00fclkede denenmeye ba\u015flad\u0131"},"content":{"rendered":"<p><figure> <span> <img decoding=\"async\" src=\"https:\/\/ekamu.net\/wp-content\/uploads\/2024\/08\/dunyanin-ilk-mrna-akciger-kanseri-asisi-turkiye-dahil-7-ulkede-denenmeye-basladi-0-sUe5uFzj.jpg\"\/> <\/span> D\u00fcnyan\u0131n ilk <strong>mRNA<\/strong> akci\u011fer kanseri a\u015f\u0131s\u0131 denemesi, aralar\u0131nda <strong>T\u00fcrkiye<\/strong>\u2019nin de bulundu\u011fu yedi \u00fclkede ba\u015flat\u0131ld\u0131. Bu \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 \u00e7al\u0131\u015fma, kanser tedavisinde <strong>devrim yaratma potansiyeline sahip<\/strong>. D\u00fcnya genelinde akci\u011fer kanseri, her y\u0131l yakla\u015f\u0131k 1.8 milyon insan\u0131n hayat\u0131n\u0131 kaybetmesine neden olarak, en fazla \u00f6l\u00fcmle sonu\u00e7lanan kanser t\u00fcr\u00fc olarak \u00f6ne \u00e7\u0131k\u0131yor. \u00d6zellikle hastal\u0131\u011f\u0131n ileri evrelerinde, t\u00fcm\u00f6rlerin v\u00fccudun di\u011fer b\u00f6lgelerine yay\u0131lmas\u0131 durumunda, hayatta kalma oranlar\u0131 olduk\u00e7a d\u00fc\u015f\u00fck seyrediyor. <\/figure>\n<p><b>Akci\u011fer kanseri i\u00e7in ilk a\u015f\u0131<\/b><\/p>\n<p><strong>BioNTech <\/strong>taraf\u0131ndan geli\u015ftirilen ve <strong>BNT116 <\/strong>olarak adland\u0131r\u0131lan a\u015f\u0131, en yayg\u0131n akci\u011fer kanseri t\u00fcr\u00fc olan <strong>k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanserini<\/strong> (NSCLC) hedef al\u0131yor. A\u015f\u0131n\u0131n amac\u0131, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bu t\u00fcr kansere \u00f6zg\u00fc t\u00fcm\u00f6r belirte\u00e7lerini tan\u0131y\u0131p sald\u0131rmas\u0131 i\u00e7in e\u011fiterek, kanser h\u00fccrelerini yok etmek ve tekrar olu\u015fmalar\u0131n\u0131 engellemek.<\/p>\n<p><strong>T\u00fcrkiye, Birle\u015fik Krall\u0131k, ABD, Almanya, \u0130spanya, Macaristan <\/strong>ve <strong>Polonya<\/strong>\u2019da y\u00fcr\u00fct\u00fclen bu deneme, akci\u011fer kanseri tedavisinde \u00f6nemli bir ad\u0131m olarak g\u00f6r\u00fcl\u00fcyor. Akci\u011fer kanseri, d\u00fcnya genelinde en fazla \u00f6l\u00fcme yol a\u00e7an kanser t\u00fcr\u00fc olup, \u00f6zellikle ileri vakalarda hayatta kalma oranlar\u0131 olduk\u00e7a d\u00fc\u015f\u00fck olan bir hastal\u0131k.<\/p>\n<figure> <span> <img decoding=\"async\" src=\"https:\/\/ekamu.net\/wp-content\/uploads\/2024\/08\/dunyanin-ilk-mrna-akciger-kanseri-asisi-turkiye-dahil-7-ulkede-denenmeye-basladi-1-s1wbla4I.jpg\"\/> <\/span> 34 ara\u015ft\u0131rma merkezinde y\u00fcr\u00fct\u00fclen<strong> birinci faz klinik deneme <\/strong>kapsam\u0131nda yakla\u015f\u0131k 130 akci\u011fer kanseri hastas\u0131, bu yenilik\u00e7i a\u015f\u0131 ile birlikte imm\u00fcnoterapi tedavisi alacak. BNT116\u2019da kullan\u0131lan mRNA teknolojisi, COVID-19 a\u015f\u0131lar\u0131ndaki teknolojiye benzer \u015fekilde \u00e7al\u0131\u015f\u0131yor; ba\u011f\u0131\u015f\u0131kl\u0131k sistemini kanser h\u00fccrelerine sald\u0131rmas\u0131 i\u00e7in uyar\u0131rken, sa\u011fl\u0131kl\u0131 h\u00fccrelere zarar vermiyor. <\/figure>\n<p>Denemeye kat\u0131lan ilk hastalardan biri olan <strong>67 <\/strong>ya\u015f\u0131ndaki bilim insan\u0131 <strong>Janusz Racz<\/strong>, bilime katk\u0131 sa\u011flama inanc\u0131yla bu denemeye kat\u0131ld\u0131\u011f\u0131n\u0131 belirtti. Racz, May\u0131s ay\u0131nda te\u015fhis edildi ve bu yeni tedavinin kanserini ortadan kald\u0131rmas\u0131na ve k\u00fcresel \u00e7aptaki etkili kanser tedavileri geli\u015ftirme \u00e7abalar\u0131na katk\u0131da bulunmas\u0131n\u0131 umuyor.<\/p>\n<p>BNT116 a\u015f\u0131s\u0131n\u0131n denemeleri, gelecekte akci\u011fer kanseri tedavisinde standart bir uygulama haline gelerek, bir\u00e7ok hastan\u0131n hayat\u0131n\u0131 kurtarma potansiyeline sahip. Deneme sonu\u00e7lar\u0131na g\u00f6re, a\u015f\u0131n\u0131n ikinci ve \u00fc\u00e7\u00fcnc\u00fc fazlar\u0131 da ger\u00e7ekle\u015ftirilerek, d\u00fcnya genelinde yayg\u0131n kullan\u0131m\u0131 planlan\u0131yor. Bu da a\u015f\u0131n\u0131n d\u00fcnya genelinde standart bir tedavi haline gelmesi ihtimalini do\u011furuyor.<\/p>\n\n<p><span style=\"display: block; width: 343.125px; color: rgb(55, 58, 60); font-size: 14px; background-color: rgb(255, 249, 236);\"><\/span><\/p>\n<p>Kaynak :\u00a0<span style=\"background-color: rgb(255, 249, 236); color: rgb(55, 58, 60); font-size: 14px;\">https:\/\/www.donanimhaber.com\/dunyanin-ilk-mrna-akciger-kanseri-asisi-icin-denemeler-basladi&#8211;181062<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>D\u00fcnyan\u0131n ilk mRNA akci\u011fer kanseri a\u015f\u0131s\u0131 denemesi, aralar\u0131nda T\u00fcrkiye\u2019nin de bulundu\u011fu yedi \u00fclkede ba\u015flat\u0131ld\u0131. Bu \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 \u00e7al\u0131\u015fma, kanser tedavisinde devrim yaratma potansiyeline sahip. D\u00fcnya genelinde akci\u011fer kanseri, her y\u0131l yakla\u015f\u0131k 1.8 &#8230;<\/p>\n","protected":false},"author":1,"featured_media":72849,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[4105,2269,16,2232,102],"class_list":["post-72848","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-teknoloji","tag-akciger-kanseri","tag-asi","tag-deneme","tag-kanser","tag-tedavi"],"_links":{"self":[{"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/posts\/72848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/comments?post=72848"}],"version-history":[{"count":1,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/posts\/72848\/revisions"}],"predecessor-version":[{"id":72852,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/posts\/72848\/revisions\/72852"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/media\/72849"}],"wp:attachment":[{"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/media?parent=72848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/categories?post=72848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ekamu.net\/index.php\/wp-json\/wp\/v2\/tags?post=72848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}